{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-26-000042","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.845932+00:00","generated_at":"2026-05-15T02:36:50.241703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance","bullets":["Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).","Growth products: LEQEMBI $168M (+74%), SKYCLARYS $151M (+22%), ZURZUVAE $55M (+100%), VUMERITY $179M (+29%), QALSODY $33M (+110%).","Proposed Apellis acquisition expected to close Q2 2026, accretive in 2027; Biogen to update guidance post-close.","FY2026 Non-GAAP EPS guidance $14.25-$15.25 (ex-Apellis); total revenue seen declining mid-single digit % vs 2025.","Pipeline: litifilimab Phase 2 CLE positive; SPINRAZA High Dose Regimen FDA approved; felzartamab rights in Greater China acquired."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-26-000042","json":"https://secwatch.observer/filing/0000875045-26-000042.json","markdown":"https://secwatch.observer/filing/0000875045-26-000042.md","text":"https://secwatch.observer/filing/0000875045-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/biib-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:36:50.241703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9626167b866b844e91eeb357d17a94d78c7d4e42","claim":"BIOGEN INC. reported the first quarter ended March 31, 2026 results: revenue $2,478, EPS GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57. Guidance raised.","evidence_excerpt":"and reported important positive new data that reinforce our confidence in the late‐stage pipeline.\" Financial Highlights Q1 '26 Q1 '25 △ r (CC * ) Total Revenue (in millions) $2,478 $2,431 2% (2)% GAAP diluted EPS $2.15 $1.64 31% N/A Non-GAAP diluted EPS $3.57 $3.02 18% N/A Note: Percent changes represented as favorable/(unfavorable) versus the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$2,478"},{"label":"EPS","value":"GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}